Cell line · CVCL_1292
HT-1376
Cancer cell line, Homo sapiens. Bladder carcinoma. 37 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. HT-1376. Cell lines, record CVCL_1292. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1292
On this page
Cell line
As Cellosaurus gives it.
- Name
- HT-1376
- Accession
- CVCL_1292
- RRID
- RRID:CVCL_1292
- Synonyms
- HT1376, HT 1376, HT 1376.T
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 58Y
- Category
- Cancer cell line
- Diseases
- Bladder carcinoma (NCIt C4912)
- Derived from
- Urinary bladder (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers37
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| An MMP-14/STAT3 feedback loop upregulates PD-L1 to drive immunosuppression and tumorigenesis in bladder cancer. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| APOBEC3 activity and DNA polymerase-ε deficiency are associated with distinct IDH1 R132 hotspot mutations. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CRB-701: A Second-generation Nectin-4-Targeted Antibody-Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Proteomic analysis of the urothelial cancer landscape. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Glutathione S-transferase omega class 1 (GSTO1)-associated large extracellular vesicles are involved in tumor-associated macrophage-mediated cisplatin resistance in bladder cancer. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Comprehensive identification of onco-exaptation events in bladder cancer cell lines revealed L1PA2-SYT1 as a prognosis-relevant event. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 37
See all 37 papersRelatives4
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | HT1376 FOXP3 | CVCL_C3H1 | Cell lines | |
| Derived from it | HT1376 FOXP3Delta3 | CVCL_C3H2 | Cell lines | |
| Derived from it | HT1376rCDDP1000 | CVCL_RR15 | Cell lines | |
| Derived from it | HT1376rGEMCI20 | CVCL_RR16 | Cell lines |
Cell banks8
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-1472 | ATCC | |
| ATCC | CRL-7927 | Discontinued | Cellosaurus |
| BCRC | 60058 | BCRC | |
| CLS | 305100 | CLS | |
| DSMZ | ACC-397 | DSMZ | |
| ECACC | 87032402 | ECACC | |
| IZSLER | BS TCL 70 | Cellosaurus | |
| KCLB | 21472 | KCLB |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1292
GET https://conductscience.org/api/cell-lines/v1/CVCL_1292/papers?page=2